
|Videos|January 21, 2021
Differentiated Thyroid Cancer with a Focus on Adverse Event Management
Author(s)Targeted Oncology
Steven Sherman, MD, FACE, provides insight on the treatment of radioactive iodine-refractory differentiated thyroid cancer and the management of adverse events.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Fast Track Designation to VS-7375 for KRAS G12D–Mutated NSCLC
2
ASCO 2026 GI Cancer Highlights: Beyond the LBAs
3
ASCO 2026 GU Cancer Highlights: Beyond the LBAs
4
FDA Approves Generic Eribulin Mesylate for Metastatic Breast Cancer
5


































